In:
Allergy, Wiley, Vol. 61, No. 7 ( 2006-07), p. 812-819
Abstract:
Background: Probiotic lactic acid bacteria (LAB) are able to modulate the host immune system and clinical trials have demonstrated that specific strains have the capacity to reduce allergic symptoms. Therefore, we aimed to evaluate the potential of recombinant LAB producing the major birch pollen allergen Bet v 1 for mucosal vaccination against birch pollen allergy. Methods: Recombinant Bet v 1‐producing Lactobacillus plantarum and Lactococcus lactis strains were constructed. Their immunogenicity was compared with purified Bet v 1 by subcutaneous immunization of mice. Intranasal application of the live recombinant strains was performed to test their immunomodulatory potency in a mouse model of birch pollen allergy. Results: Bet v 1 produced by the LAB was recognized by monoclonal anti‐Bet v 1 and IgE antibodies from birch pollen‐allergic patients. Systemic immunization with the recombinant strains induced significantly lower IgG1/IgG2a ratios compared with purified Bet v 1. Intranasal pretreatment led to reduced allergen‐specific IgE vs enhanced IgG2a levels and reduced interleukin (IL)‐5 production of splenocytes in vitro , indicating a shift towards non‐allergic T‐helper‐1 (Th1) responses. Airway inflammation, i.e. eosinophils and IL‐5 in lung lavages, was reduced using either Bet v 1‐producing or control strains. Allergen‐specific secretory IgA responses were enhanced in lungs and intestines after pretreatment with only the Bet v 1‐producing strains. Conclusions: Mucosal vaccination with live recombinant LAB, leading to a shift towards non‐allergic immune responses along with enhanced allergen‐specific mucosal IgA levels offers a promising approach to prevent systemic and local allergic immune responses.
Type of Medium:
Online Resource
ISSN:
0105-4538
,
1398-9995
DOI:
10.1111/all.2006.61.issue-7
DOI:
10.1111/j.1398-9995.2006.01071.x
Language:
English
Publisher:
Wiley
Publication Date:
2006
detail.hit.zdb_id:
2003114-2
